EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Effect of proprotein convertase subtilisin kexin 9 inhibitors on platelet aggregation in patients with and without diabetes

Mario Crisci, Federica Ilardi, Rachele Manzo, Felice Gragnano, Roberta Paolillo, Giuseppe Giugliano, Orlando Piro, Emanuele Cigala, Ida Monteforte, Veronica D'Oria, Enzo Venga, Alessandra Marotta und 5 weitere

Nutrition, Metabolism and Cardiovascular Diseases · 2026-09 · 36 (9) · 104728

DOI: 10.1016/j.numecd.2026.104728 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nutrition, Metabolism and Cardiovascular Diseases, 2026-09. Verfasst von Mario Crisci und 16 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, AORN dei Colli Monaldi Hospital, Naples, Italy. Hauptthemen laut MEDLINE: Platelet Aggregation, PCSK9 Inhibitors, Antibodies, Monoclonal, Humanized, Serine Proteinase Inhibitors. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND AND AIM: The impact of proprotein convertase subtilisin/kexin 9 (PCSK9) inhibitors on platelet reactivity in the setting of diabetes mellitus (DM) has not been adequately investigated. METHODS AND RESULTS: Out of 52 outpatients with atherosclerotic cardiovascular disease (ASCVD) with an indication for PCSK9 inhibitor alirocumab, 37 patients (mean age 68.1 ± 5.6 years, 62% males) were included in the study and retrospectively divided into two groups according to the presence of DM (DM+/DM-). A blood sample for platelet function testing was collected at baseline (T0), before initiation of alirocumab, and after 3 months of therapy (T90). Light transmission aggregometry was performed to study platelet aggregation, and results were expressed as percentage of maximum platelet aggregation (MPA). At 90-day follow-up, a significant reduction of total cholesterol and low-density lipoprotein cholesterol levels compared to baseline was observed in both DM+ and DM-groups. At baseline, MPA were comparable between the two groups. At T90, only in the DM + cohort, platelet aggregation induced by adenosine diphosphate (ADP) and arachidonic acid (AA) was significantly reduced compared to baseline (ADP 20 μM: 56.00 ± 28.67% vs 63.16 ± 33.69%, at T90 vs T0 respectively, p = 0.011; AA 1 mM: 28.68 ± 40.10% vs 41.74 ± 46.85%, p = 0.025). No significant change in platelet function from baseline was observed in patients DM- (p > 0.05 for all comparisons). CONCLUSION: The PCSK9 inhibitor alirocumab significantly reduced AA and ADP residual platelet aggregation after 90 days of therapy in patients with ASCVD and diabetes, but not in those without diabetes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Platelet AggregationPCSK9 InhibitorsAntibodies, Monoclonal, HumanizedSerine Proteinase InhibitorsDiabetes MellitusDyslipidemiasAtherosclerosisBlood PlateletsPlatelet Aggregation InhibitorsAnticholesteremic AgentsHumansMaleFemaleAgedRetrospective StudiesBiomarkersTreatment OutcomeTime FactorsMiddle AgedProprotein Convertase 9Platelet Function TestsCholesterol, LDL

Stichwörter der Autor:innen

AlirocumabDiabetes mellitusPCSK9 inhibitorsPlatelet aggregation

Substanzen

PCSK9 InhibitorsBiomarkersalirocumabAntibodies, Monoclonal, HumanizedPCSK9 protein, humanProprotein Convertase 9Serine Proteinase InhibitorsCholesterol, LDLPlatelet Aggregation InhibitorsAnticholesteremic Agents

Autor:innen und Institutionen

  • Division of Cardiology, AORN dei Colli Monaldi Hospital, Naples, Italy.
  • Division of Cardiology, Department of Advanced Biomedical Sciences, University Federico II of Naples, Italy. Electronic address: federica.ilardi@unina.it.
  • Division of Cardiology, Department of Advanced Biomedical Sciences, University Federico II of Naples, Italy.
  • University of Campania Luigi Vanvitelli, Naples, Italy.
  • Department of Cardiac Surgery and Transplants, AORN dei Colli Monaldi Hospital, Naples, Italy.
  • Department of Prevention, UOC SIAN, ASL Napoli 2 Nord, Italy.

Zitieren

APA

Crisci, M., Ilardi, F., Manzo, R., Gragnano, F., Paolillo, R., Giugliano, G., Piro, O., Cigala, E., Monteforte, I., D'Oria, V., Venga, E., Marotta, A., Salvato, A., Calabrò, P., Esposito, G., Di Lorenzo, E., & De Feo, M. (2026). Effect of proprotein convertase subtilisin kexin 9 inhibitors on platelet aggregation in patients with and without diabetes. Nutrition, Metabolism and Cardiovascular Diseases, 36(9), 104728. https://doi.org/10.1016/j.numecd.2026.104728

Vancouver

Crisci M, Ilardi F, Manzo R, Gragnano F, Paolillo R, Giugliano G, et al. Effect of proprotein convertase subtilisin kexin 9 inhibitors on platelet aggregation in patients with and without diabetes. Nutrition, Metabolism and Cardiovascular Diseases. 2026;36(9):104728. doi:10.1016/j.numecd.2026.104728

BibTeX
@article{Crisci2026,
  author = {Crisci, Mario and Ilardi, Federica and Manzo, Rachele and Gragnano, Felice and Paolillo, Roberta and Giugliano, Giuseppe and Piro, Orlando and Cigala, Emanuele and Monteforte, Ida and D'Oria, Veronica and Venga, Enzo and Marotta, Alessandra and Salvato, Angela and Calabrò, Paolo and Esposito, Giovanni and Di Lorenzo, Emilio and De Feo, Marisa},
  title = {Effect of proprotein convertase subtilisin kexin 9 inhibitors on platelet aggregation in patients with and without diabetes},
  journal = {Nutrition, Metabolism and Cardiovascular Diseases},
  year = {2026},
  volume = {36},
  number = {9},
  pages = {104728},
  doi = {10.1016/j.numecd.2026.104728}
}
Kostenlos starten →